RNA sequence-specific mediators of RNA interference
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
A61K-048/00
출원번호
US-0897756
(2010-10-04)
등록번호
US-8742092
(2014-06-03)
우선권정보
EP-00126325 (2000-12-01)
발명자
/ 주소
Tuschl, Thomas
Sharp, Phillip A.
Zamore, Phillip D.
Bartel, David P.
출원인 / 주소
University of Massachusetts
대리인 / 주소
Lando & Anastasi, LLP
인용정보
피인용 횟수 :
13인용 특허 :
44
초록▼
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the ab
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
대표청구항▼
1. A pharmaceutical composition comprising: an isolated double-stranded RNA molecule of from 21 to 23 nucleotides, comprising two separate RNA strands which are not covalently linked, that is perfectly complementary to a cellular mRNA and mediates RNA interference of the mRNA; andan appropriate carr
1. A pharmaceutical composition comprising: an isolated double-stranded RNA molecule of from 21 to 23 nucleotides, comprising two separate RNA strands which are not covalently linked, that is perfectly complementary to a cellular mRNA and mediates RNA interference of the mRNA; andan appropriate carrier. 2. A pharmaceutical composition comprising: an isolated double-stranded RNA molecule of from 21 to 23 nucleotides, which is chemically synthesized in the form of two separate RNA strands which are not covalently linked, that is perfectly complementary to a cellular mRNA and mediates RNA interference of the mRNA; andan appropriate carrier. 3. A composition comprising an isolated, chemically synthesized double-stranded RNA molecule of 21 or 23 nucleotides, comprising two separate RNA strands which are not covalently linked, that is perfectly complementary to a mammalian cellular mRNA and mediates RNA interference by directing cleavage of the mRNA to which it corresponds, wherein cleavage is directed within the region of sequence correspondence with the isolated RNA molecule. 4. A pharmaceutical composition comprising: an isolated double-stranded RNA molecule of 21 or 23 nucleotides, in the form of two separate RNA strands which are not covalently linked, that is perfectly complementary to an mRNA and mediates RNA interference of the mRNA, wherein the isolated RNA molecule comprises one or more of a non-naturally occurring nucleotide, or a deoxyribonucleotide, or a non-standard nucleotide; andan appropriate carrier. 5. The pharmaceutical composition of claim 1, wherein a strand of the isolated RNA molecule is 21 nucleotides in length. 6. The pharmaceutical composition of claim 1, wherein a strand of the isolated RNA molecule is 22 nucleotides in length. 7. The pharmaceutical composition of claim 1, wherein a strand of the isolated RNA molecule is 23 nucleotides in length. 8. The pharmaceutical composition of claim 1, wherein the cellular mRNA is a human mRNA. 9. The pharmaceutical composition of claim 1, wherein the isolated RNA molecule comprises a terminal 3′ hydroxyl group. 10. The composition of claim 3, further comprising an appropriate carrier, wherein the composition is a pharmaceutical composition. 11. A pharmaceutical composition comprising: an isolated double-stranded RNA molecule of 21 or 23 nucleotides, comprising two separate RNA strands which are not covalently linked, said RNA molecule comprising an RNA strand that is perfectly complementary to an mRNA to mediate RNA interference of the mRNA, wherein the mRNA encodes a protein whose presence in a human is associated with a disease or an undesirable condition; andan appropriate carrier. 12. The composition of claim 11, wherein the isolated RNA molecule is chemically synthesized. 13. The composition of claim 11, wherein the RNA molecule comprises one or more of a non-naturally occurring nucleotide, or a deoxyribonucleotide, or a non-standard nucleotide. 14. A pharmaceutical composition comprising: an isolated double-stranded RNA molecule of from 21 to 23 nucleotides, comprising two separate RNA strands which are not covalently linked, said RNA molecule comprising an RNA strand that is perfectly complementary to an mRNA to mediate RNA interference of the mRNA, wherein the double-stranded RNA molecule reduces expression of the mRNA and the mRNA encodes a protein whose presence in a human is associated with a disease or an undesirable condition; andan appropriate carrier. 15. The composition of claim 14, wherein the isolated RNA is chemically synthesized. 16. The composition of claim 14, wherein the RNA molecule comprises one or more of a non-naturally occurring nucleotide, or a deoxyribonucleotide, or a non-standard nucleotide. 17. A composition comprising an isolated double-stranded RNA molecule of 21 or 23 nucleotides in length, comprising two RNA strands which are not covalently linked, wherein the RNA molecule comprises an RNA strand that is perfectly complementary to an mRNA to mediate RNA interference. 18. The composition of claim 17, wherein the double-stranded RNA molecule is chemically synthesized. 19. The composition of claim 17, wherein the double-stranded RNA molecule comprises one or more non-naturally occurring nucleotides. 20. The composition of claim 17, wherein the double-stranded RNA molecule comprises one or more non-standard nucleotides. 21. The composition of claim 17, wherein the double-stranded RNA molecule comprises one or more deoxyribonucleotides. 22. The composition of claim 17, wherein the double-stranded RNA molecule comprises a terminal 3′ hydroxyl group. 23. The composition of claim 17, wherein each RNA strand of the double-stranded RNA molecule comprises a terminal 3′ hydroxyl group. 24. The composition of claim 17, wherein the mRNA is a cellular mRNA. 25. The composition of claim 17, wherein the mRNA is a mammalian mRNA. 26. The composition of claim 17, wherein the mRNA is a human mRNA. 27. The composition of claim 17, wherein the mRNA encodes a protein that is associated with a disease or an undesirable condition. 28. The composition of claim 17, wherein the mRNA is a viral mRNA. 29. The composition of claim 17, wherein a strand of the double-stranded RNA molecule is 21 nucleotides in length. 30. The composition of claim 17, wherein a strand of the double-stranded RNA molecule is 23 nucleotides in length. 31. The composition of claim 17, further comprising an appropriate carrier. 32. A composition comprising an isolated, chemically synthesized double-stranded RNA molecule of from 21 to 23 nucleotides in length, in the form of two RNA strands which are not covalently linked, wherein: (i) the double-stranded RNA molecule comprises a strand that is perfectly complementary to an mRNA to mediate RNA interference; and(ii) the double-stranded RNA molecule comprises one or more non-naturally occurring nucleotides,wherein the mRNA encodes a cellular protein or a viral protein. 33. The composition of claim 32, wherein the double-stranded RNA molecule comprises a terminal 3′ hydroxyl group. 34. The composition of claim 32, wherein a strand of the double-stranded RNA molecule is 21 nucleotides in length. 35. The composition of claim 32, wherein a strand of the double-stranded RNA molecule is 22 nucleotides in length. 36. The composition of claim 32, wherein a strand of the double-stranded RNA molecule is 23 nucleotides in length. 37. The composition of claim 32, wherein the mRNA is a cellular mRNA. 38. The composition of claim 32, wherein the mRNA is a mammalian mRNA. 39. The composition of claim 32, wherein the mRNA is a human mRNA. 40. The composition of claim 32, wherein the mRNA encodes a protein that is associated with a disease or an undesirable condition. 41. The composition of claim 32, wherein the mRNA is a viral mRNA. 42. The composition of claim 32, further comprising an appropriate carrier. 43. The pharmaceutical composition of claim 1, wherein the mRNA is a mammalian mRNA. 44. The pharmaceutical composition of claim 2, wherein the mRNA is a mammalian mRNA. 45. The composition of claim 17, wherein the mRNA is an oncogene mRNA. 46. The composition of claim 32, wherein the mRNA is an oncogene mRNA. 47. The composition of claim 17, wherein both strands of the double-stranded RNA molecule are 21 nucleotides in length. 48. The composition of claim 17, wherein both strands of the double-stranded RNA molecule are 23 nucleotides in length. 49. The composition of claim 32, wherein both strands of the double-stranded RNA molecule are 21 nucleotides in length. 50. The composition of claim 32, wherein both strands of the double-stranded RNA molecule are 22 nucleotides in length. 51. The composition of claim 32, wherein both strands of the double-stranded RNA molecule are 23 nucleotides in length.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
Chris A. Buhr ; Mark Matteucci, 2' Modified oligonucleotides.
Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Carlsbad CA) Cowsert Lex M. (Carlsbad CA), Antisense oligonucleotide inhibition of papillomavirus.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Noonberg Sarah B. (Berkeley CA) Hunt C. Anthony (San Francisco CA), In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides deriv.
Thompson Peter (Danville CA) Lund-Johannsen Fridjtof (Fremont CA), Method for identifying cells committed to apoptosis by determining cellular phosphotyrosine content.
Francis P. Tally ; Jianshi Tao ; Philip A. Wendler ; Gene Connelly ; Paul L. Gallant ; Xiaoyu Shen ; Jiansu Zhang, Method for identifying validated target and assay combinations for drug development.
Eckstein Fritz (Gottingen DEX) Pieken Wolfgang (Boulder CO) Benseler Fritz (Gleichen/Etzborn DEX) Olsen David B. (West Point PA) Williams David M. (Cambridge GB2) Heidenreich Olaf (Gottingen DEX), Modified ribozymes.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Draper Kenneth G. (Boulder CO) Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Leucadia CA) Hanecak Ronnie C. (San Clemente CA) Anderson Kevin P. (Carlsbad CA), Oligonucleotide therapies for modulating the effects of herpes viruses.
Cancilla, Mark; Cunningham, James J.; Flanagan, Michael W.; Haringsma, Henry J.; Kenski, Denise; Stanton, Matthew G.; Stirdivant, Steven M.; Willingham, Aarron, RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA).
Cancilla, Mark; Cunningham, James John; Flanagan, William Michael; Haringsma, Henry J.; Kenski, Denise M.; Stanton, Matthew G.; Stirdivant, Steven M.; Willingham, Aarron T., RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.